The annual Genes and Cancer meeting continues to attract participants from all over the world with diverse interests relating to the molecular biology of cancer. The 2006 meeting covered the broad areas of gene expression, cancer stem cells, tumour suppressors, signalling, nuclear structure and genome stability. This report describes a selection of some of the highlights of the meeting, focusing largely on unpublished data. My apologies to all those whose work could not be discussed in detail because of space constraints.
The first day started with a stimulating series of lectures, regarding the regulation of gene expression. Reuven Agami from the Netherlands Cancer Institute, Amsterdam, described a series of screens for microRNAs (miRNAs) that can regulate the expression of genes important for tumourigenesis. miRNAs are around 22 nucleotides long and act by impeding the expression of target genes. Each miRNA becomes incorporated into the RNA induced silencing complex (RISC), and the miRNA then directs RISC to the 3 0 untranslated region of a mRNA, causing either degradation of the mRNA or inhibition of translation. miRNAs therefore allow cells to regulate gene expression post-translationally, and could potentially explain how the expression of particular tumour-suppressor genes is inhibited in human tumours despite the apparent absence of mutations in such genes. To screen for miRNAs that can regulate expression of the gene encoding p27, a tumour suppressor that inhibits the function of certain cyclin-dependent kinases (CDKs), a test mRNA expressing green fluorescent protein (GFP) was generated, bearing the three prime untranslated region (3 0 UTR) from the p27 gene. The test mRNA was then introduced into cells together with a library expressing human miRNAs. In this way, the 221/222 cluster of miRNAs was found to reduce expression of GFP, and a similar effect was observed with an analogous mRNA expressing luciferase and also bearing the 3 0 UTR of the p27 gene. The effect was shown to be specific, as it could be blocked either by point mutations in the 3 0 UTR of p27, or via an 'antagomir' RNA molecule that blocked the function of the 221/222 miRNAs. These data raise the interesting possibility that such miRNAs may regulate the endogenous p27 gene in cells, perhaps at the translational level.
Peter Verrijzer from the Erasmus University Medical Centre, Rotterdam, discussed the role of the SNF5 subunit of the human SWI/SNF ATP-dependent chromatin remodelling complex as a tumour suppressor. Inactivation of SNF5 is associated with malignant rhabdoid tumours (MRTs), and reexpression of SNF5 in MRT cells blocks growth and induces cellular senescence. Expression of the p16 tumour suppressoritself implicated in senescence -is induced under such conditions, in contrast to the p21 CDK inhibitor, or the p14ARF tumour suppressor. Moreover, previous work had shown that p16 is required for the induction of senescence by SNF5. Chromatin immunoprecipitation experiments were used to show that SNF5 is recruited to specific elements within the INK4/ARF locus, namely to the promoters of p15 and p16, but not to the promoter of p14ARF. These and other experiments raise the possibility that SNF5 may induce senescence by directly promoting the expression of p16.
Other speakers in this session included Lin He from Greg Hannon's group at Cold Spring Harbor Laboratory, New York, who spoke about the role of miRNAs as oncogenes during lymphomagenesis, Stefan Roberts from the University of Manchester who discussed the Wilms' tumour suppressor protein WT1 and Martin Eilers from the Philipps-University, Marburg, who talked about the role of Myc and Miz1 in regulating the Atr/Chk1 pathway.
The first day closed with a wonderful keynote lecture by David Allis from the Rockefeller University, New York, entitled, 'Beyond the Double Helix: Writing and Reading the Histone Code'. Trimethylation of the lysine 4 residue of histone H3 (H3K4me3) marks the transcriptional start site of nearly all active genes, and recent work has shown that this mark is 'written' by the histone methyltranferase MLL1 (for mixed lineage leukaemia) and 'read' by a specific subunit of the nucleosome remodelling factor (NURF). The BPTF subunit of NURF (bromodomain and PHD finger transcription factor) has a number of so-called 'plant homeodomain' (PHD) fingers, as well as a bromodomain that is located at the C-terminus of the protein. The PHD finger immediately preceding the bromodomain is responsible for binding H3K4me3. In contrast, the bromodomain recognises acetylated lysine 16 of histone H4, a mark donated by the histone acetyltransferase MOF (for maleless on the first). Each interaction on its own may be insufficient to allow high affinity binding, and it now appears that both domains collaborate to allow simultaneous binding to histones H3 and H4, leading to the idea of a 'single nucleosome model' that may explain the docking of factors such as BPTF. This paradigm may apply to other factors that interact with nucleosomes, and other proteins are known to contain adjacent PHD and bromodomains, separated by a linker region analogous to that of BPTF.
The second day started with a session on 'tumour biology' that included two lectures on cancer stem cells. Michael Clarke from the Stanford School of Medicine, California, discussed studies that aim to identify cancer stem cells on the basis of gene expression patterns. Different populations of human breast cancer cells were separated by virtue of distinct cell surface markers, and the ability of each population to induce tumours in mice was then determined. This led to the identification of cell populations that are enriched in potential 'cancer stem cells'. The gene expression profile of these cells was then compared with that of other populations of cells that could not induce tumours. In this way, around 200 genes were found to define a potential 'cancer stem cell signature' of gene expression. Clinical samples were used to generate gene expression profiles of whole tumours, to investigate the prognostic value of the stem cell signature. Tumours with a profile closer to the stem cell signature were found to be associated with a worse prognosis than those with a profile less similar to the stem cell signature.
Dominique Bonnet from the London Research Institute of Cancer Research UK discussed the study of leukaemia stem cells. Here again, different populations of cells from a tumour (acute myeloid leukaemia or AML) were separated on the basis of cell surface markers and assayed for their ability to engraft and induce tumours in mice. In this way, a potential stem cell population was identified that represents less than 2 % of the tumour. The question then considered was how such leukaemia stem cells might be targeted specifically for cancer therapies, without harming normal cells. One possible solution is to target pathways that may be specifically important in tumours to protect the cancer stem cells from apoptosis. For example, the NF-KB transcription factor is constitutively active in AML and may serve as a survival factor. Work by Craig Jordan's group of the University of Rochester, New York, has shown that parthenolide inhibits NF-KB and ablates AML cells in vitro. Importantly, the mouse model system has been used to show that parthenolide blocks engraftment of AML cells but not of normal cells.
Daniel Peeper from the Netherlands Cancer Institute described a screen to identify novel tumour suppressors that mediate the induction of cellular senescence by a mutant form of the B-RAF kinase, which normally functions as a primary effector of the Ras oncogene product. The B-RAF (V600E) mutation, which is highly prevalent in human tumours including melanoma, causes an increase in kinase activity. Expression of B-RAF (V600E) in cultured primary human melanocytes induces a brief burst of proliferation, followed by cellular senescence. Human melanocytic nevi (moles) that carry the B-RAF (V600E) mutation upregulate p16 INK4A and can remain in a state of growth arrest for decades. However, this growth arrest is not strictly dependent upon p16
INK4A
. Other potential effectors of this phenotype were identified in a screen that used microarrays to look for genes with increased expression under such conditions. The expression of candidate genes was then inhibited by RNA interference, as inactivation of important effector genes should bypass senescence. In this way, various candidates were identified, including the gene encoding the cytokine interleukin-6 (IL-6). Expression of IL-6 is indeed associated with senescence and is induced by B-RAF (V600E). Other interleukins are also upregulated by B-RAF (V600E), suggesting the action of a common upstream regulatory factor that may be controlled by B-RAF. The C/EBP b transcription factor is required for the expression of various interleukin genes, and a gel mobility shift assay was used to provide evidence that C/ EBP b activity may indeed be induced by B-RAF. Moreover, inactivation of C/EBP b by RNA interference was sufficient to block the onset of cellular senescence in response to expression of B-RAF (V600E).
Other speakers in this session included Jeffrey Pollard from the Albert Einstein College of Medicine, New York, who described the role of macrophages in the progression and metastasis of tumours, Kairbaan Hodivala-Dilke from Cancer Research UK's clinical centre in London, who discussed the role of integrin proteins in angiogenesis and Gordon Peters from Cancer Research UK's London Research Institute, who talked about the regulation and function of the INK4b-ARF-INK4a tumour suppressor locus.
In the final session of the second day, concerning 'signalling and cancer', Dario Alessi from the Protein Phosphorylation Unit of the Medical Research Council, Dundee, discussed the LKB1 protein kinase. Mutation of LKB1 is thought be to responsible for induction of tumours in Peutz-Jeghers syndrome and expression of LKB1 in cancer cell lines that lack the kinase arrests cells in the G1 phase of the cell cycle. Previous work showed that LKB1 phosphorylates the 'T-loop' of the AMP-activated protein kinase (AMPK1), and thus promotes activation of AMPK in the presence of AMP. In a mouse model system, muscle contraction causes an increase in AMPK activity, and this is dependent upon Lkb1. This raises the interesting possibility that increased exercise may actually help to protect cells against cancer, at least in some circumstances, by stimulating AMPK activity.
The session also included contributions from Neal Rosen from Sloan-Kettering Institute, New York, who described the use of small-molecule inhibitors to study the role of MAP kinases in tumour biology, Chris Marshall from the Institute of Cancer Research, London, who discussed the role of the Rho-GTPase in angiogenesis and tumour cell movement and Dafna BarSagi from New York University, who spoke about the regulation of Ras signalling in cancer initiation and progression. The day ended on a relaxed note with the conference dinner followed by a traditional ceilidh.
The meeting closed in the following morning with a session on nuclear structure and genome stability. Iain Mattaj from EMBL, Heidelberg, discussed how assembly of the nuclear envelope is regulated in higher eukaryotes. The MEL-28 protein (maternal effect lethal) was originally identified in Caenorhabditis elegans and associates first with the nuclear envelope during interphase, and then with kinetochores during mitosis. Studies with Xenopus egg extracts identified the loading of MEL-28 onto chromatin as the earliest known stage in the assembly of nuclear pores after mitosis. MEL-28 is then required for loading of the Nup107-160 pore complex with which it associates. Conversely, Nup107-160 is not required for loading of MEL-28. Interestingly, depletion of either MEL-28 or Nup107-160 from the egg extracts blocks formation of nuclear pores but does not inhibit formation of the nuclear envelope. In contrast, defects in later stages of pore formation induce a block to the assembly of the nuclear envelope. These findings suggest that cells may have evolved a regulatory mechanism, which can detect defects in forming nuclear pores and then block the subsequent assembly of the nuclear envelope. Complete absence of nuclear pores, resulting from depletion of MEL-28 or Nup107-160, may fail to activate such a regulatory mechanism.
Joachim Lingner from ISREC, Lausanne, discussed how cells protect the ends of their chromosomes by regulating the formation of telomeres. Previous work with the budding yeast, Saccharomyces cerevisiae, showed that not all chromosome ends are extended by telomerase in every cell cycle, and that the frequency of elongation increases for telomeres as their lengths decrease. It now seems that Tel1 kinase is required for this regulatory mechanism to function properly, although the relevant substrates remain to be identified. To address the processivity of telomerase, cells that expressed both wild-type telomerase and also a mutated form that adds a distinct sequence were used. Both mutated and wild-type telomere sequences could be added to the same chromosome end in a given cell cycle, implying that there is considerable turnover of telomerase, and that the enzyme may normally add less than three repeats per binding event. However, on very short telomeres, the processivity seems to increase so that nine or 10 repeats can be added.
Other contributors to this session included Wendy Bickmore from the Medical Research Council's Human Genetics Unit, Edinburgh, who described how the localisation of genes within the nucleus is regulated during development and differentiation, Rene Medema from the University Medical Center, Utrecht, who spoke about the role of Polo-like kinase in recovery from checkpoint arrest and Karim Labib from Cancer Research UK's Paterson Institute, Manchester, who discussed how the progression of eukaryotic DNA replication forks is regulated in eukaryotic cells.
The organisers thank all the sponsors for their generosity: the list includes Abcam, AICR, AstraZeneca, Breakthrough, Cancer Research UK, EACR, Exiqon, GlaxoSmithKline, Kudos and Yorkshire Cancer Research. We also thank all the participants for contributing to this fascinating meeting. The 2007 Genes and Cancer meeting will be held between 10th and 12th December and for online registration, please visit our official website www.genesandcancer.org.
